BIOAGE Labs R&D per Employee

What does BIOAGE Labs do? BIOAGE Labs Inc generates revenue through the development and potential commercialization of therapeutic product candidates for metabolic diseases. Its lead product azelaprag, an orally available small molecule agonist of the apelin receptor, is being tested in a Phase II trial combined with tirzepatide for obesity treatment in older adults. The company also develops NLRP3 inhibitors as preclinical programs targeting neuroinflammation-driven diseases. BIOAGE Labs focuses on clinical-stage biopharmaceutical development for metabolic aging pathways, with products targeting obesity therapy and body composition improvement in patients using incretin drugs. The company's primary market segments include patients with obesity requiring treatment, particularly older adults, and those needing therapies addressing neuroinflammation. BIOAGE Labs targets healthcare providers and pharmaceutical partners interested in metabolic disease treatments and neuroinflammation therapies. The company's products are developed for clinical use rather than direct consumer sales, with revenue anticipated from future partnerships or product sales upon successful clinical trials and regulatory approvals. BIOAGE Labs' business model centers on advancing its pipeline of therapeutic candidates through clinical trials, leveraging its discovery platform built on human longevity data. The company's focus on metabolic aging pathways and its lead candidate azelaprag for obesity treatment in combination with incretin drugs like tirzepatide positions it within the pharmaceutical industry. The company's preclinical programs for NLRP3 inhibitors represent additional potential revenue streams once development progresses to clinical stages. BIOAGE Labs is one of the most popular companies on Eulerpool.